Many of today's most celebrated drugs are designed to hit only one biological target with great precision. But a novel clinical trial aims to turn this idea on its head by using 'network pharmacology' to more effectively tackle a common neurological disorder affecting limb movement. Claire Ainsworth looks into how medicine's proverbial 'magic bullet' might soon give way to a more sophisticated arsenal.
This is a preview of subscription content, log in via an institution to check access.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ainsworth, C. Networking for new drugs. Nat Med 17, 1166–1168 (2011). https://doi.org/10.1038/nm1011-1166
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm1011-1166
- Springer Nature America, Inc.
This article is cited by
-
Combining two repurposed drugs as a promising approach for Alzheimer's disease therapy
Scientific Reports (2015)
-
VNP: Interactive Visual Network Pharmacology of Diseases, Targets, and Drugs
CPT: Pharmacometrics & Systems Pharmacology (2014)
-
Searching for the Ideal Antiepileptogenic Agent in Experimental Models: Single Treatment Versus Combinatorial Treatment Strategies
Neurotherapeutics (2014)
-
An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A
Orphanet Journal of Rare Diseases (2014)
-
The chemical interactome space between the human host and the genetically defined gut metabotypes
The ISME Journal (2013)